当前位置:首页 - 行情中心 - 华森制药(002907) - 财务分析 - 资产负债表

华森制药

(002907)

  

流通市值:43.21亿  总市值:58.42亿
流通股本:3.09亿   总股本:4.18亿

资产负债表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
流动资产:
货币资金453,534,336.74508,524,357.02547,122,756.1503,528,894
应收票据及应收账款236,665,438.02258,920,186.68298,991,371.53315,032,400.19
其中:应收票据58,572,852.9177,228,053.0787,255,698.0898,188,032.09
应收账款178,092,585.11181,692,133.61211,735,673.45216,844,368.1
预付款项9,494,640.569,841,657.7613,164,170.8413,977,340.43
其他应收款合计5,975,7065,564,821.823,934,817.099,587,740.49
存货163,297,486.89153,086,515.85150,376,214.54114,755,546.52
其他流动资产3,892,883.278,905,809.621,959,889.4167,466.73
流动资产平衡项目0000
流动资产合计872,860,491.48944,843,348.751,015,549,219.51956,949,388.36
非流动资产:
长期股权投资24,682,946.6126,661,075.7421,442,338.1925,975,029.5
其他非流动金融资产74,023,493.7174,106,933.4673,500,00058,500,000
投资性房地产71,594,199.8517,801,663.218,581,801.4818,969,812.9
固定资产585,087,363.37651,848,957.35590,172,096.12604,288,354.84
在建工程20,380,934.7422,151,055.7621,750,616.3317,515,933.99
使用权资产321,574.82335,553.76110,672.85137,777.44
无形资产109,623,188.74103,392,608.9103,036,229.5775,256,797.49
开发支出48,035,742.547,341,054.0942,024,272.5439,962,738.7
长期待摊费用3,935,777.713,446,030.973,851,517.244,047,424.17
递延所得税资产16,166,053.5418,365,481.4518,464,449.9618,661,173.4
其他非流动资产18,982,577.0111,333,849.1529,235,505.7546,402,300.58
非流动资产平衡项目0000
非流动资产合计972,833,852.6976,784,263.83922,169,500.03909,717,343.01
资产平衡项目0000
资产总计1,845,694,344.081,921,627,612.581,937,718,719.541,866,666,731.37
流动负债:
短期借款-70,000,00070,000,000-
应付票据及应付账款48,467,199.4552,743,536.3259,477,953.6848,042,921.45
应付账款48,467,199.4552,743,536.3259,477,953.6848,042,921.45
预收款项770,555.8904,308.5772,347.19910,614.83
合同负债1,367,888.541,618,132.23,315,397.465,814,603.21
应付职工薪酬7,544,752.598,037,613.917,476,830.823,609,845.28
应交税费9,163,344.186,629,261.427,916,547.9418,882,278.78
其他应付款合计101,178,197.31109,436,698.54107,161,523.19113,229,882.68
其中:应付利息-48,611.153,472.22-
一年内到期的非流动负债196,843.79147,954.2122,109.33112,157.27
其他流动负债181,700.09203,567.09432,203.4717,398.31
流动负债平衡项目0000
流动负债合计168,870,481.75249,721,072.19256,574,912.99211,319,701.81
非流动负债:
租赁负债153,480.15223,483.1861,999.5757,723.8
递延收益44,793,311.943,332,324.5642,079,582.7843,594,773.99
递延所得税负债1,122,309.691,182,779.781,246,990.591,304,537.24
非流动负债平衡项目0000
非流动负债合计46,069,101.7444,738,587.5243,388,572.9444,957,035.03
负债平衡项目0000
负债合计214,939,583.49294,459,659.71299,963,485.93256,276,736.84
所有者权益(或股东权益):
实收资本(或股本)417,596,314417,596,314417,596,314417,596,314
资本公积458,885,615.52458,601,075.91452,035,953.08454,715,825.95
其他综合收益538,929.03649,547.95-168,212.61-112,782.67
盈余公积88,211,140.6788,211,140.6788,211,140.6788,211,140.67
未分配利润665,522,761.37662,109,874.34680,080,038.47649,979,496.58
归属于母公司股东权益平衡项目0000
归属于母公司股东权益合计1,630,754,760.591,627,167,952.871,637,755,233.611,610,389,994.53
股东权益平衡项目0000
股东权益合计1,630,754,760.591,627,167,952.871,637,755,233.611,610,389,994.53
负债和股东权益合计1,845,694,344.081,921,627,612.581,937,718,719.541,866,666,731.37
公告日期2023-10-272023-08-222023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑